TOMMI ALCORN: Open Payments
NPI 1538717871 · HOUSTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$749 in 34 payments from 17 companies in 2025. Trend: 2023 $446 · 2024 $394 · 2025 $749
Food & beverage: $749
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 5 | $133 |
| Novo Nordisk Inc | 4 | $77 |
| Verona Pharma, Inc. | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Baxter Healthcare | 1 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| AstraZeneca Pharmaceuticals LP | 3 | $44 |
| GENZYME CORPORATION | 2 | $44 |
| Insulet Corporation | 2 | $41 |
| Grifols USA, LLC | 2 | $33 |
Products named: DUPIXENT, REXULTI, Ohtuvayre, Hillrom - Vest System Model 205 Acute Care, CAPLYTA, Omnipod, Wegovy, Prolastin-C Liquid.
Industry payments across MO — which companies pay providers there.
